Egis in the World
Our products reach 100 countries
Our portfolio consists of 653 products. Our main focus lies on treating diseases of the cardiovascular and central nervous systems.
Learn moreEgis activities extend to every field of the pharmaceutical value chain
Click here to learn moreEgis is an innovation-oriented generic pharma company, one of the regional industry leaders.
Click here to learn moreBalázs Vándor is appointed to the position of the Company’s Chief Financial Officer.
One of the pillars of our corporate culture is innovation. We do not only talk about it, but ensure the flow of ideas with annual forums that offer space for making proposals in connection with scientific research, manufacturing, how to make our administrative process more effective and the latest item on our agenda: digitalization.
The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.